The National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center – Jefferson Health (SKCC) is a nationally recognized center for practice-changing discovery and comprehensive cancer treatment, offering a depth and breadth of experience in all aspects of cancer from the laboratory to the clinic. Our mission is to improve the lives of cancer patients and their families through compassion, innovation, and breakthrough discoveries. For more information, visit sidneykimmelcancercenter.jeffersonhealth.org.
Dr. Gomella on the Evolution of AR Inhibitors in Prostate Cancer
March 19th 2020Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.
Gomella Calls for Increased Genetic Testing in Prostate Cancer
April 18th 2019Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.
ACP Releases Breast Cancer Screening Guidance Statements for Asymptomatic, Average-Risk Women
April 9th 2019For women at average risk for breast cancer who are between the ages of 40 and 49 years, clinicians should have a personalized approach on whether their patients should be screened with mammography prior to the age of 50.
Sidney Kimmel Cancer Center at Jefferson Joins Global Network
The Sidney Kimmel Cancer Center – Jefferson Health announces a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which launched today in the United States and China.
Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC
July 13th 2018Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.
Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer
May 23rd 2018Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.
Dr. Trabulsi Defines Locally Advanced Prostate Cancer
May 7th 2018Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.
Ongoing Trial to Determine Role of Degarelix in Lowering Cardiovascular AEs in Prostate Cancer
April 12th 2018The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.
Dr. Kelly on the Importance of Local Control in Locally Advanced Prostate Cancer
April 10th 2018William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, director, Division of the Solid Tumor Oncology, Sidney Kimmel Cancer Center, discusses the evolution of local control in locally advanced prostate cancer.
Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC
February 20th 2018Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.